September 10, 2021 11:01 AM EDTUpdated 02:35 PM
News Briefing

Canada's Bausch to pay $300M in an­titrust set­tle­ment; Cardiff re­leas­es da­ta on mCRC tri­al

Paul Schloesser

Associate Editor

Cana­di­an phar­ma com­pa­ny Bausch Health has agreed to set­tle an an­titrust class-ac­tion suit from a 2015 price in­crease.
Ac­cord­ing to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times